Over the past 3 months, 15 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the ...

All of BluePrint’s Pro Series 426ci Hemi crate engines have this in common: all start with a brand-new BGE/Hellcat cast-iron block, a forged rotating assembly consisting of a 4.050-inch-stroke forged ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Blueprint Medicines (NASDAQ:BPMC) in the last three months. In the table below, you'll find a ...

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: In the last 3 months, 17 analysts have offered 12-month price targets for Blueprint Medicines. The ...